P2-272: Gemsitabine plus cisplatine therapy in local advanced NSCLC

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283980.15084.4d ◽

2007 ◽

Vol 2 (8) ◽

pp. S680

Author(s):

Berna E. Komurcuoglu ◽

Hamide Aydogan ◽

Mine Gayaf ◽

Enver Yalnız ◽

Emel Ozden

Keyword(s):

Advanced Nsclc ◽

Download Full-text

Split-course Thoracic Radiotherapy Combined With Nab-paclitaxel Plus Nedaplatin for Local Advanced NSCLC With Impaired Baseline Pulmonary Function

Case Medical Research ◽

10.31525/ct1-nct04212052 ◽

2019 ◽

Author(s):

Keyword(s):

Pulmonary Function ◽

Advanced Nsclc ◽

Thoracic Radiotherapy ◽

Download Full-text

Split-course Chemoradiotherapy for Local Advanced NSCLC With Impaired Baseline Pulmonary Function

Case Medical Research ◽

10.31525/ct1-nct03900117 ◽

2019 ◽

Author(s):

Keyword(s):

Pulmonary Function ◽

Advanced Nsclc ◽

Download Full-text

P3.14-016 Research About Different Administration Mode of Endostar for Combining with Concurrent Chemoradiotherapy in Local Advanced NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1789 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2337

Author(s):

J. Li ◽

Z. Qiu

Keyword(s):

Concurrent Chemoradiotherapy ◽

Advanced Nsclc ◽

Download Full-text

P2.14-011 Recombinant Human Endostatin (Endostar) Combined with Concurrent Intensity Modulated Radiation Therapy for Elderly Local Advanced NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1383 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2179

Author(s):

Q. Chen ◽

Q. Xie ◽

Q. Shi

Keyword(s):

Radiation Therapy ◽

Advanced Nsclc ◽

Intensity Modulated Radiation Therapy ◽

Recombinant Human Endostatin ◽

Intensity Modulated ◽

Download Full-text

Review for "MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti PD‐1 immunotherapy in patients with advanced NSCLC"

10.1002/eji.202048534/v2/review1 ◽

2020 ◽

Keyword(s):

T Cells ◽

Download Full-text

Review for "MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti PD‐1 immunotherapy in patients with advanced NSCLC"

10.1002/eji.202048534/v1/review2 ◽

2019 ◽

Keyword(s):

T Cells ◽

Download Full-text

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs. docetaxel in patients with advanced NSCLC (POPLAR)

Pneumologie ◽

10.1055/s-0036-1572212 ◽

2016 ◽

Vol 70 (S 01) ◽

Author(s):

A Rittmeyer ◽

A Spira ◽

K Park ◽

J Mazieres ◽

J Vansteenkiste ◽

...

Keyword(s):

Phase Ii ◽

Advanced Nsclc ◽

Phase Ii Study ◽

Predictive Biomarker ◽

Randomized Phase Ii

Download Full-text

Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the Ph III study OAK

Pneumologie ◽

10.1055/s-0037-1619265 ◽

2018 ◽

Vol 72 (S 01) ◽

pp. S56-S56

Author(s):

N Reinmuth ◽

K Syrigos ◽

J Mazieres ◽

D Cortinovis ◽

R Dziadziuszko ◽

...

Keyword(s):

Adverse Events ◽

Download Full-text

Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Local Advanced or Metastatic, HER2 Positive Breast Cancer.

Case Medical Research ◽

10.31525/ct1-nct03944499 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Solid Tumors ◽

Phase 1 ◽

Advanced Solid Tumors ◽

Her2 Positive ◽

Phase 1 Study ◽

Her2 Positive Breast Cancer ◽

Local Advanced ◽

Positive Breast Cancer

Download Full-text

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Case Medical Research ◽

10.31525/ct1-nct03989310 ◽

2019 ◽

Author(s):

Keyword(s):

Pancreatic Cancer ◽

Phase I ◽

Metastatic Pancreatic Cancer ◽

Open Label Phase ◽

Download Full-text